A proven, dynamic biopharma leader with an established track record of implementing and overseeing corporate strategy, executing financings and strategic collaborations, and building and managing business and finance functions.
Kyle Kuvalanka brings over 20 years of experience in senior leadership roles in the biopharmaceutical industry. Prior to joining ROME, he was the Chief Financial Officer and Chief Operating Officer (COO) at Goldfinch Bio, where he oversaw the business, finance, commercial and strategy functions and led a strategic process that resulted in the out-license of the lead assets. Before that, he served as COO and Principal Financial and Accounting Officer at Syros Pharmaceuticals and Chief Business Officer and Principal Financial and Accounting Officer at Blueprint Medicines. In these roles, Kyle helped to transition the companies from early-stage start-ups to publicly traded, clinical-stage organizations, having built the business and finance functions, led the execution of financings, including the companies’ initial public offerings, and led the negotiations of the companies’ early strategic collaborations. Before joining Blueprint Medicines, Kyle worked in roles of increasing responsibility over twelve years at Millennium: The Takeda Oncology Company, including as Vice President of Business Development and Corporate Strategy.
Kyle holds an MBA from The Wharton School of Business, University of Pennsylvania, and a B.A. with Honors from Wesleyan University.